Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls

Executive Summary

FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.
Advertisement

Related Content

FDA Standardizing REMS Re-Enrollment Procedures
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Abstral REMS Assessment To Look At Impact On Patient Access, Health Care System
Abstral REMS Assessment To Look At Impact On Patient Access, Health Care System
The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
If Opioid REMS Mandates Prescriber Training, Firms May Ask DEA For Help
FDA's Opioid REMS Proposal Has Narrow Focus On Education
FDA's Opioid REMS Proposal Has Narrow Focus On Education
FDA Wants More REMS Authority To Speed Negotiations With Sponsors

Topics

Advertisement
UsernamePublicRestriction

Register

PS053037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel